The British medical device maker said that some 95.4% of the shareholders affected by the tie-up voted for the deal, with 4.6% of those shares voting against. Overall, the votes to approve the merger amounted to 62.4% of total BTG shares and the votes against were 0.03%, BTG said.
Earlier this week Marlborough, Mass.-based Boston Scientific said it closed a $4.3 billion debt round it plans use to defray the cost of buying BTG.
The £8.40-per-share offer, worth about $4.24 billion (£3.3 billion), is slated to close in mid-2019. The purchase price is a 36.6% premium over BTG’s closing price the day before the Nov. 20 announcement and a 51.0% premium over the stock’s 90-day volume-weighted average price.
BTG’s largest division makes devices for oncology and vascular conditions; the company also makes overdose and antivenin drugs for snakebite.